Alumis (NASDAQ:ALMS – Get Free Report) was upgraded by HC Wainwright from a “neutral” rating to a “buy” rating in a research note issued on Wednesday, Marketbeat Ratings reports. The brokerage presently has a $15.00 price objective on the stock, down from their prior price objective of $25.00. HC Wainwright’s price target points to a potential upside of 58.39% from the company’s current price.
A number of other analysts have also weighed in on ALMS. Citigroup reissued an “overweight” rating on shares of Alumis in a research note on Tuesday. Chardan Capital lifted their target price on shares of Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, May 19th. Guggenheim upped their price target on shares of Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, May 15th. Wells Fargo & Company reissued an “overweight” rating on shares of Alumis in a research report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a research report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.82.
Get Our Latest Stock Analysis on Alumis
Alumis Trading Down 56.6%
Alumis (NASDAQ:ALMS – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.34). Alumis had a negative net margin of 5,933.46% and a negative return on equity of 93.15%. The company had revenue of $1.66 million for the quarter, compared to analysts’ expectations of $3.65 million. As a group, equities research analysts forecast that Alumis will post -2.95 earnings per share for the current fiscal year.
Insider Activity
In other news, insider Jorn Drappa sold 2,447 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $64,527.39. Following the completion of the transaction, the insider owned 56,892 shares in the company, valued at $1,500,242.04. This trade represents a 4.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David M. Goldstein sold 2,596 shares of Alumis stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $68,456.52. Following the sale, the insider owned 30,970 shares in the company, valued at $816,678.90. This represents a 7.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 19,953 shares of company stock worth $534,311. 33.70% of the stock is owned by company insiders.
Hedge Funds Weigh In On Alumis
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. KBC Group NV bought a new stake in shares of Alumis during the 1st quarter valued at $42,000. Strs Ohio increased its stake in shares of Alumis by 300.0% in the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $44,000 after acquiring an additional 1,500 shares in the last quarter. State of Wyoming bought a new position in shares of Alumis in the 1st quarter worth about $57,000. EverSource Wealth Advisors LLC lifted its position in Alumis by 600.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 3,131 shares of the company’s stock valued at $69,000 after acquiring an additional 2,684 shares during the period. Finally, Assetmark Inc. purchased a new position in Alumis during the 1st quarter valued at about $92,000.
Key Stories Impacting Alumis
Here are the key news stories impacting Alumis this week:
- Positive Sentiment: Alumis said patients with a prespecified, high interferon gene signature (IFNGS-high) showed robust responses, supporting plans to advance envudeucitinib into a Phase 3 lupus study focused on this subgroup. The drug was generally well tolerated, with no new safety signals. Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in SLE
- Positive Sentiment: The company remains on track to submit a U.S. application for envudeucitinib in moderate-to-severe plaque psoriasis during the fourth quarter of 2026. Analysts and commentary continue to view psoriasis as an important source of potential value despite the lupus disappointment. Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside
- Neutral Sentiment: Trading in ALMS was temporarily halted pending news as investors assessed the trial announcement. Unusually heavy put-option activity, with put volume substantially above normal, indicated elevated hedging or bearish positioning ahead of the results.
- Negative Sentiment: The Phase 2b LUMUS trial failed to meet its primary and secondary endpoints in the overall SLE population. The result undermines the drug’s broad lupus opportunity and prompted a steep selloff because Alumis has no commercial product and its valuation is heavily dependent on envudeucitinib. Alumis Phase 2b LUMUS Trial Misses Endpoints
- Negative Sentiment: Management’s decision to pursue a late-stage lupus study only in the IFNGS-high subgroup may reduce the addressable market and adds regulatory and execution risk. Investors will likely focus on the strength and durability of that subgroup data, Phase 3 design, and the psoriasis filing timeline. Alumis Eyes Late-Stage Lupus Study Despite Trial Miss
Alumis Company Profile
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Articles
- Five stocks we like better than Alumis
- What Does Apple’s TV Price Hike Say About Where the Stock Is Heading?
- Will the Most Successful Quantum Firms Be Software Companies?
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
